Free Cardiology CME

This CME activity discusses the diagnosis and treatment of ATTR-CM and highlights key updates on ATTR-CM treatment presented at the HFSA Annual Scientific Meeting 2025 and AHA Scientific Sessions 2025.

In this online, self-learning activity:

Pulmonary hypertension (PH) comprises five etiologic groups; Group I, pulmonary arterial hypertension (PAH), is a precapillary entity defined hemodynamically by right‑heart catheterization: mean pulmonary artery pressure >20 mm Hg, pulmonary artery wedge pressure ≤15 mm Hg, and pulmonary vascular resistance ≥3 Wood units. PAH is uncommon but consequential; estimates place U.S. prevalence near 10.6 per million, with contemporary data showing rarity yet meaningful population burden. Sex differences are notable—women predominate, while men may experience more severe trajectories—underscoring the need for sex‑aware assessment. Multinational reviews suggest incidence and prevalence remain non‑trivial, with enduring morbidity and mortality despite therapeutic gains.

This educational activity reviews emerging clinical evidence and evolving treatment strategies for transthyretin amyloid cardiomyopathy (ATTR-CM), with a focus on recently approved disease-modifying therapies. Learners will examine key clinical trial data related to efficacy, safety, quality of life, functional outcomes, and long-term disease stabilization, as well as explore how these findings may be applied in patient scenarios representative of contemporary clinical practice.

In this MedX activity, Michael Blaha, MD, explores the evolving landscape of low-density lipoprotein cholesterol (LDL-C) management in patients with atherosclerotic cardiovascular disease (ASCVD), with a focus on the current role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and how emerging novel PCSK9 inhibitor formulations may be integrated into clinical practice as they become available.

This webcast focuses on the role of wearable devices in the timely identification of atrial fibrillation (AF) and the evolving evidence around the rationale for and efficacy/safety of early rhythm control strategies, including guideline recommendations and expert insights on the use of antiarrhythmic drugs (AADs) and catheter ablation. It also incorporates an AI-powered patient simulator as a method by which participants can practice how they engage patients in shared decision-making discussions regarding rhythm control strategies

In this #CME #MedX, get the latest guidance on managing hypertrophic cardiomyopathy (HCM), including confirming an obstructive HCM (oHCM) diagnosis, integrating recent clinical information on cardiac myosin inhibitor treatments, and addressing patients’ concerns and questions about living with HCM.